Navigation Links
iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference
Date:6/3/2008

NASHUA, N.H., June 3 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced that Ken Ferry, Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer of iCAD, will be presenting a corporate update at the Seventh Annual Needham and Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008 at 2:00 p.m., (Eastern Daylight Time) at The New York Palace Hotel in New York City. The presentation will be followed by a breakout session scheduled to take place at 2:30 p.m.

Management will be available for one-on-one meetings with investors participating in the Needham and Company Conference. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your Needham and Company representative.

The presentation will be webcast live at http://www.wsw.com/webcast/needham25/icad/ and at http://www.icadmed.com on the "Investors" section of the company's web site.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 2,000 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.

For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com

For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com

For Public Relations, contact Jill Testagrossa of Schwartz Communications at 781-684-0770 or via e-mail at icad@schwartz-pr.com.


'/>"/>
SOURCE iCAD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
3. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
4. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
5. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
8. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)...  Genprex, Inc. a biopharmaceutical company focused on ... announced that it has retained ICR Healthcare, a ... and advisory firm, to develop and implement an ... investor relations, public relations and digital communications to ... Genprex and its lead candidate Oncoprex, which is ...
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):